INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2002

In patients with type 2 diabetes and dyslipidemia, policosanol reduced LDL-C by 29.9% and increased HDL-C more effectively than lovastatin.

In a pilot, double-blind study, 36 patients with dyslipidemia and type 2 diabetes on a cholesterol-lowering diet were randomized to receive policosanol (10 mg/day) or lovastatin (20 mg/day) for 8 weeks. Policosanol significantly lowered LDL-C by 29.9%, total cholesterol by 21.1%, triglycerides by 13.6%, and increased HDL-C by 12.5%, outperforming lovastatin in raising HDL-C and reducing lipid ratios (p < 0.05). Policosanol also improved lag time of LDL peroxidation by 20.9% and plasma antioxidant activity by 24.2%. Both treatments reduced lipid peroxidation markers and were well tolerated, though the authors note further studies with larger sample sizes are required.

Study type
Pilot, randomized, double-blind study
Who was studied
36 patients with dyslipidemia and type 2 diabetes mellitus
What was measured
Lipid profile and lipid peroxidation markers

THE PAPER

Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus.

Castaño G, Menéndez R, Más R, Amor A, Fernández JL, González RL, Lezcay M, Alvarez E. Int J Clin Pharmacol Res, 2002.

PubMed 12837046 ↗

Heart & arteriesDiabetes & blood sugar

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.